Meeting
2022 ASCO Annual Meeting
Pan-cancer (ca) analysis of the safety and efficacy of immune checkpoint inhibitors (ICI) in patients (pts) living with HIV (PLWH): Results from the international CATCH-IT consortium.
Authors
Talal El Zarif
Dana Farber Cancer Institute, Boston, MA
Talal El Zarif , Amin Nassar , Elio Adib , Jiaming Huang , Rana R. McKay , Ryan Dobbs , Nazli Dizman , Claire Drolen , Elie Kozaily , Anwaar Saeed , Caroline Nebhan , Michael Lorentsen , Javier Baena , Lindsey Baden , Ramya Ramaswami , Toni K. Choueiri , Kathryn Anne Lurain , Guru P. Sonpavde , Abdul Rafeh Naqash , Alessia Dalla Pria
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Other Checkpoint Inhibitors (Non-PD1/PDL1, Monotherapy, or Combination)
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 2649)
DOI
10.1200/JCO.2022.40.16_suppl.2649
Abstract #
2649
Poster Bd #
303
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
A phase II, open-label study of tomivosertib (eFT508) added on to continued checkpoint inhibitor therapy in patients (pts) with insufficient response to single-agent treatment.
First Author: Anthony B. El-Khoueiry
First Author: Jeddeo Paul
Poster
2024 ASCO Annual Meeting
Early combination with mycophenolate mofetil for immune-related hepatitis in patients with solid tumors treated with immune checkpoint inhibitors.
First Author: Yukiko Shimoda Igawa
Poster
2023 ASCO Genitourinary Cancers Symposium
Safety and efficacy of immune checkpoint inhibitors (ICI) in advanced penile squamous cell carcinoma (PeCa): An international study from the Global Society of Rare Genitourinary Tumors (GSRGT).
First Author: Talal El Zarif